Skip to main content

Table 3 Association between cardiac function parameters and Torsades de Point (TdP) risk category of antipsychotics

From: Clinicians’ adherence to clinical practice guidelines for cardiac function monitoring during antipsychotic treatment: a retrospective report on 434 patients with severe mental illness

  AP Torsades de Point risk category, N (%)   
Monitoring parameters A B C χ 2 P-value
Presence of ECG testing before AP treatment 48 (29.6) 229 (20.0) 3 (1.1) 12.9 0.002
Presence of ECG testing during AP treatment 46 (28.4) 375 (32.8) 16 (38.1) 1.9 0.3
Presence of electrolytes levels before AP treatment 47 (29.0) 246 (21.5) 2 (4.8) 12.1 0.002
Presence of electrolytes levels during AP treatment 51 (31.5) 358 (31.3) 18 (42.9) 2.5 0.3
Presence of personal history of pre-existing cardiac disease 5 (3.1) 57 (5.0) 4 (9.5) 3.1 0.2
Number of cardiac function parameters tested
 0 63 (38.9) 519 (45.4) 20 (47.6) 10.3a 0.41a
 1 27 (16.7) 190 (16.6) 5 (11.9)
 2 55 (34.0) 298 (26.0) 13 (31.0)
 3 8 (4.9) 73 (6.4) 4 (9.5)
 4 9 (5.6) 56 (4.9) 0 (0.0)
 5 0 (0.0) 8 (0.0) 0 (0.0)
  1. Category A: drugs with known risk of inducing TdP
  2. Category B: drugs with possible risk of inducing TdP
  3. Category C: drugs with conditional risk of TdP
  4. AP antipsychotic
  5. ECG electrocardiogram
  6. a χ 21000 sample bootstrap